Clinical Trial Update: Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax [NA]

View source ↗

Summary

This completed clinical trial assessed the effect of Loteprednol etabonate (Lotemax) on ocular surface inflammatory mediators in Sjögren's syndrome, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• Lotemax (Loteprednol etabonate)

Snippet

Sponsor: University of Rochester | Conditions: Sjogren's Disease | NA | Status: COMPLETED | Results posted: 2015-10-16